Cisapride and risk of cardiac complications;Cisapride e rischio di complicanze cardiache

Minerva Pediatrica

Volumn 51, Issue 9-10, 1999, Pages 309-311

  Cataldo, F ^a  

^a Clinica Pediatrica R   (Italy)

Author keywords

Adverse effects; Cardiovascular diseases etiology; Child; Cisapride; Electrocardiography; Infant

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; CALCIUM; CIMETIDINE; CISAPRIDE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; MACROLIDE; MAGNESIUM; POTASSIUM; PROKINETIC AGENT; RANITIDINE;

CARDIOTOXICITY; CHILD; ELECTROLYTE DISTURBANCE; GESTATIONAL AGE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFANT; LIVER DYSFUNCTION; LIVER METABOLISM; LONG QT SYNDROME; NEWBORN; PARASYMPATHETIC INNERVATION; PREMATURITY; REVIEW; RISK FACTOR;

AGE FACTORS; ARRHYTHMIA; CISAPRIDE; ELECTROCARDIOGRAPHY; GASTROINTESTINAL AGENTS; HUMANS; INFANT, NEWBORN;

EID: 0033383739     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Tack J, Coremans G, Janssens J. A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Drug Saf 1995;12:384-92.
2. CSM/MCA Current problems in pharmacovigilance. 1998:24.
3. Bernardini S, Semame DS, Sgro C. Effects of cysapride on QTc interval in neonates. Arch Dis Child 1997;77:F241-3.
4. Valdes L, Champel V, Oliver C. Syncope with long QT interval in a 39 day-old infant treated with cisapride. Arch Pediatr 1997;4:535-7.
5. Lewin MB, Bryant RM, Fenrich AL. Cisapride induced long QT interval. J Ped 1996;128:279-81.
6. Pettignano R, Chamblin CR, Daesey E. Cisapride induced dysrythmia in a pediatric patient receiving extra-corporeal life support. Crit Care Med 1996;24:1268-71.
7. Schwartz PJ, Strambo-Badiale M, Segantini A. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998;338:1709-14.
8. Bedu A, Lupoglazoff JM, Faure C. Cisapride high dosage and long QT interval (Letter). J Ped 1997;130:164.
9. Bran S, Murray WA, Hiesch IB. Long QT interval syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
10. Lupoglazoff JM, Bedu M, Fauer C. Allongement de l'espage QT sous cysapride chez le nouveau-né et le nourisson. Arch Pediatr 1997;4:509-14.
11. Landee A. The risks and benefits of cisapride in premature neonates, infants and children. Arch Dis Child 1998;79:469-70.
12. Gunasekaran TS, Dubrow I. Cisapride induced long QT interval :what is the role of ranitidine? J Pediatr 1997;130:679-80.
13. Bedford TA, Rowbotham D. Cisapride: drug interactions of clinical significance. Drug Safetey 1996;15(3): 167-75.
14. Vandeplas Y, Ashkenazi A, Belli D. A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children : a report from a working group on gastro-oesophageal reflux disease. Eur J Ped 1993;152: 704-11.
15. Cucchiara S, Staiano AM, Boccieri A. Effects of cisapride on parametres of oesophageal motility and on the prolonged intraesophageal pH test in infants with gastrooesophageal reflux disease. Gut 1990;31:21-5.
16. Van Eygen M, Van Ravensteyn H. Effect of cisapride on excessive regurgitation in infants. Clin Ther 1989;11: 669-77.
17. Khongphatthaneyothin A, Lane J, Thomas D. Effects of cisapride on QT interval in children. J Ped 1998;133: 51-6.
18. Hill SL, Evangelista JK, Pizzi AM. Proarrhythmia associated with cisapride in children. Pediatrics 1998;101: 1053-6.
19. Levine A. Fogelman R. Siroto L, Dinari G. QT interval in children and infants receiving cisapride. Pediatrics 1998;101:E9.